| Metric | Value ($ M) |
|---|---|
| Revenue | 0.50 |
| Total Income | 0.50 |
| Expenditure | 12.20 |
| PBT | — |
| Net Profit | -10.57 |
| OPM | — |
| NPM | — |
| EPS | -0.05 |
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108
11 Aug 2026 · 11 Aug, 1:53 am
Summary
Palisade Bio reported its financial results for the second quarter ended June 30, 2026, alongside a business update focused on the advancement of its PALI-2108 program. The company expects to enroll the first patient in its Phase 2 ASCENTRA-UC trial in the second half of 2026, with primary efficacy results due in the second half of 2027. Additionally, an IND submission for the Phase 2 ASCENTRA-CD trial is anticipated in the second half of 2026. The company recognized $0.5 million in license revenue for the quarter and reported a net loss of $10.6 million ($0.05 per share). Palisade Bio ended the quarter with $125.2 million in cash, sufficient to fund operations through major clinical development milestones.
Key Highlights
- 1
Palisade Bio reported financial results for the second quarter ended June 30, 2026, and provided a business update.
- 2
Enrollment of the first patient for the Phase 2 ASCENTRA-UC trial of PALI-2108 is expected in the second half of 2026, with primary efficacy results anticipated in the second half of 2027.
- 3
An Investigational New Drug (IND) application for the Phase 2 ASCENTRA-CD trial of PALI-2108 for Crohn's disease is expected in the second half of 2026.
- 4
The company recognized license revenue of $0.5 million for the three months ended June 30, 2026, related to a milestone achievement with Newsoara.
- 5
Net loss for the three months ended June 30, 2026, was $10.6 million, or a net loss of $0.05 per share.
- 6
As of June 30, 2026, the Company had $125.2 million in cash and cash equivalents, which is expected to support operations through key Phase 2 clinical development milestones.
Management Comments
JD Finley
The second quarter marked a decisive transition for Palisade Bio as we completed the regulatory and operational work required to advance PALI-2108 into Phase 2 development. With FDA clearance of our IND, encouraging Phase 1 results and a strong financial position, we expect to commence the Phase 2 ASCENTRA-UC trial in the second half of 2026. PALI-2108 was engineered for targeted activation within the gastrointestinal tract, with the goal of delivering sustained PDE4 inhibition while improving tolerability and convenience. We believe the ASCENTRA-UC Phase 2 trial represents a significant opportunity to demonstrate that differentiated profile in a larger patient population and establish PALI-2108 as a potentially best-in-class, once-daily oral therapy for IBD.
Mitch Jones
Crohn’s disease is a core component of the PALI-2108 clinical development program and is advancing in parallel with ASCENTRA-UC. We believe that PALI-2108’s targeted activation and localized delivery in both the ileum and colon are particularly relevant to Crohn’s disease, which can affect multiple regions of the gastrointestinal tract. We are finalizing the design of the Phase 2 ASCENTRA-CD trial and expect to submit an IND in the second half of 2026. With active programs in both Crohn’s disease and ulcerative colitis, PALI-2108 is positioned to address the two largest indications within IBD.
Informational and educational content only. Not investment advice.